The Relative Strength (RS) Rating for Tandem Diabetes Care climbed into a new percentile Tuesday, with a rise from 67 to 80.
IBD's proprietary RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against that of all other stocks.
Over 100 years of market history shows that the best stocks tend to have an RS Rating of above 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
While Tandem Diabetes Care is not near an ideal buy point right now, see if it is able to form and break out of a proper chart pattern.
Tandem Diabetes Care posted 0% EPS growth in the latest quarterly report. Sales increased 13%. Keep an eye out for the company's next round of numbers on or around Nov. 6.
The company holds the No. 62 rank among its peers in the Medical-Products industry group. Bioventus, Insulet and ResMed are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
